AbClon

Your hope, we keep

AbClon was founded in 2010, is headquartered in Seoul, South Korea, and has $26.1M in recorded funding across 2 rounds.

Headquarters
Seoul
Founded
2010
Business Model
B2B
Website
abclon.com
Total Funding
$26.1M
Last Round
$18.2M Convertible NoteOct 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.

About

AbClon is a South Korean biopharmaceutical company founded in 2010 in Seoul that specializes in developing next-generation antibody-based cancer therapeutics, including CAR-T cell therapies, bispecific antibodies, and novel epitope-targeting antibody drugs. Its proprietary platforms — CAR-T, NEST (Novel Epitope Screening Technology), and AffiMab — are designed to address both hematologic malignancies and solid tumors. AbClon's lead CAR-T asset AT101 is in Phase 2 clinical trials in Korea for blood cancers, and its antibody AC101 has received Orphan Drug Designation from the European Commission for gastric cancer. The company has attracted significant strategic investment, including a ₩10 billion stake from pharmaceutical firm Chong Kun Dang, and has licensed assets internationally including to China's Henlius Biotech.

Summary

AbClon is a Biotech company based in Seoul, South Korea, founded in 2010. It has raised $26.1M in total across 2 rounds, most recently a $18.2M Convertible Note round in Oct 2025. Investors include DSC Investment and Paratus Investment.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

ConvertiblePerpetual Convertible BondsOct 2025
$18.2M

Sign up to see all 2 events

Funding: Convertible Note through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AbClon on Indexed.vc
<a href="https://indexed.vc/companies/abclon"><img src="https://indexed.vc/api/badge/company/abclon" alt="AbClon on Indexed.vc" width="260" height="76" /></a>